Alembic Pharmaceuticals Ltd logo

Alembic Pharmaceuticals Ltd

APLLTD NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹16,381 Cr
Volatility
Moderate
P/E Ratio
23.39
EBITDA
₹1,173 Cr
Return on Equity
11.83%
Debt to Equity
0.25
Book Value
₹288.7
EPS
₹32.05
52W High
₹1,002
52W Low
₹635.8

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Alembic Pharmaceuticals Ltd insights

55 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 35.7%

Weaknesses

5
  • Stock is trading at 2.85 times its book value
  • The company has delivered a poor sales growth of 6.37% over past five years.
  • Tax rate seems low
  • Company has a low return on equity of 12.7% over last 3 years.
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
10.20% ↘
Net Income Growth
15.26% ↗
Cash Flow Change
789.87% ↗
ROE
5.44% ↗
ROCE
-12.89% ↘
EBITDA Margin (Avg.)
1.28% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk medium

Alembic Pharmaceuticals trades at a market cap of Rs 16,472 Cr with a PE of 24x and dividend yield of 1.43%. The company shows a TTM sales growth acceleration to 14% and profit growth of 26%, but its 5-year compounded profit growth remains negative at -9% and stock CAGR over 5 years is just 2%.

Bull Case 7
  • TTM sales growth has accelerated to 14%, significantly above the 5-year CAGR of 6% and 3-year CAGR of 9%, indicating improving revenue momentum
  • TTM profit growth of 26% and 3-year compounded profit growth of 28% signal a strong earnings recovery cycle
  • Healthy dividend payout ratio of 35.7% demonstrates management commitment to returning capital to shareholders
  • Dividend yield of 1.43% provides reasonable income support relative to pharma sector peers
  • ROE has recovered to 13% in the last year, matching the 3-year average of 13% and showing stability in return generation
  • 10-year compounded sales CAGR of 9% indicates a consistent long-term revenue base despite near-term volatility
  • PE of 24x is reasonable for a mid-cap pharma company showing 26% TTM profit growth, implying a PEG ratio below 1 on trailing earnings growth
Bear Case 8
  • 5-year compounded profit growth is negative at -9%, indicating a prolonged earnings decline before the recent recovery
  • 5-year sales CAGR of only 6.37% reflects poor top-line growth over a meaningful period
  • Stock price CAGR of just 2% over both 3 and 5 years shows the market has not rewarded the company despite recent profit recovery
  • Price-to-book of 2.92x is elevated given the 3-year ROE of only 12.7%, suggesting limited value creation above cost of equity
  • 10-year compounded profit growth of 0% means the company has generated no incremental earnings over a full decade
  • 10-year stock CAGR of just 3% has significantly underperformed broader market indices over the same period
  • Low tax rate flagged as a concern may indicate unsustainable tax benefits that could normalize and compress future earnings
  • Potential capitalization of interest costs raises questions about true operating profitability and debt servicing burden

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 17h ago
Headwinds 1
  • US branded business margin dilution Aug 10

    Management noted 150 bps margin dilution from the new US branded business in FY27, though positive profit contributions are expected from FY28 onwards.

Positives 3
  • FY27 revenue outlook upgraded mid-teens Aug 10

    Alembic reported 26% revenue surge in Q1FY27 and raised full-year growth outlook to mid-teens, driven by US generics segment growing mid-to-high teens.

  • 15+ new US product launches planned Aug 4

    Alembic plans to introduce more than 15 new products in the US market by FY27, expanding its generics portfolio.

  • USFDA approval for Prucalopride Tablets Jul 28

    Secured final USFDA approval for Prucalopride Tablets (1 mg and 2 mg), addressing a $100 million market opportunity and raising total ANDA approvals to 245.

Neutral 2
  • AGM approves financials and dividend Aug 5

    16th AGM concluded on Aug 5, 2026 with shareholders approving FY26 financials, dividend declaration, and board appointments including a new independent director.

  • Q1FY27 earnings call hosted Aug 4

    Post-results conference call held on August 4, 2026 at 5:30 PM IST for analysts and institutional investors; audio recording made available on official website.

TL;DR: Alembic Pharmaceuticals is executing well on US generics growth with a strong Q1FY27 (26% revenue surge) and upgraded full-year guidance to mid-teens. The pipeline is robust with 245 ANDA approvals and 15+ new US launches planned. Near-term margin headwind of 150 bps from the US branded segment is the key risk, but management expects this to turn profitable by FY28. The trend is clearly improving with momentum in the US business driving the upgrade cycle.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,486
1,595
1,631
1,517
1,562
1,648
1,693
1,770
1,711
1,910
1,876
1,848
2,150
Expenses
1,287
1,387
1,364
1,257
1,325
1,409
1,433
1,498
1,430
1,594
1,585
1,620
1,818
Operating Profit
199
208
266
260
237
239
260
271
281
316
292
228
332
OPM %
13%
13%
16%
17%
15%
15%
15%
15%
16%
17%
16%
12%
15%
Other Income
12
10
3
4
2
30
10
14
6
8
-27
2
15
Interest
14
16
15
11
13
19
22
25
24
24
23
23
28
Depreciation
66
68
69
69
69
71
70
69
74
76
80
89
98
PBT
130
135
185
183
157
180
178
192
190
224
162
119
222
Tax %
7%
-1%
2%
3%
14%
15%
23%
18%
19%
18%
18%
-70%
22%
Net Profit
121
137
180
178
135
153
138
157
154
184
132
202
172
EPS in Rs
6.14
6.95
9.18
9.07
6.85
7.8
7.04
7.98
7.85
9.4
6.76
10.31
8.8
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
2,056
3,166
3,105
3,131
3,935
4,606
5,393
5,306
5,653
6,229
6,672
7,345
7,784
Expenses
1,653
2,159
2,490
2,488
3,061
3,383
3,913
4,432
4,970
5,296
5,664
6,224
6,617
Operating Profit
403
1,007
615
643
874
1,223
1,480
874
682
932
1,008
1,121
1,167
OPM %
20%
32%
20%
21%
22%
27%
27%
16%
12%
15%
15%
15%
15%
Other Income
4
7
2
7
9
-39
87
56
-2
28
56
-14
-1
Interest
4
5
5
3
18
27
16
18
50
56
79
94
98
Depreciation
44
72
83
105
115
157
183
287
275
273
279
319
342
PBT
359
936
529
541
749
1,000
1,368
625
355
632
707
694
726
Tax %
21%
23%
23%
22%
21%
20%
19%
17%
4%
3%
18%
3%
—
Net Profit
283
720
403
413
583
801
1,146
521
342
616
582
671
690
EPS in Rs
15.01
38.2
21.39
21.89
31
43.97
58.33
26.5
17.4
31.33
29.68
34.33
35.27
Div. Payout %
23%
9%
19%
18%
18%
23%
24%
38%
46%
35%
37%
35%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
38
38
38
38
38
38
39
39
39
39
39
39
Reserves
847
1,560
1,865
2,182
2,681
3,182
5,028
5,198
4,331
4,779
5,152
5,636
Borrowings
264
114
89
708
1,128
1,747
584
717
722
513
1,258
1,430
Other Liabilities
493
718
698
1,013
931
1,022
1,058
1,167
1,090
1,114
1,325
1,658
Total Liabilities
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
8,763
Fixed Assets
547
708
799
993
1,158
1,552
1,788
1,798
2,398
2,547
2,524
3,081
CWIP
83
93
396
1,010
1,551
1,846
2,183
2,304
601
524
837
683
Investments
2
87
50
42
49
18
236
118
96
93
127
141
Other Assets
1,009
1,541
1,444
1,896
2,019
2,573
2,502
2,902
3,087
3,281
4,285
4,858
Total Assets
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
8,763
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
172
948
329
312
812
449
1,463
552
724
803
88
783
Investing
-256
-307
-486
-884
-756
-731
-840
-372
-448
-321
-568
-506
Financing
87
-224
-129
503
59
155
-597
-217
-262
-438
444
-164
Net Cash Flow
3
417
-286
-69
115
-127
26
-37
14
45
-37
113
Free Cash Flow
-52
647
348
-495
49
-285
804
128
282
487
-466
290
CFO/OP
60
114
73
70
112
56
115
77
115
88
16
79
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
64
40
40
61
45
69
24
56
68
60
77
73
Inventory Days
196
266
269
302
356
417
431
406
315
350
466
462
Days Payable
166
264
213
313
237
220
194
178
145
157
179
154
Cash Conversion Cycle
94
42
96
51
164
266
261
283
237
253
363
381
Working Capital Days
32
36
61
69
24
50
73
74
77
88
87
87
ROCE %
38%
66%
29%
22%
23%
24%
26%
11%
7%
13%
13%
13%

Shareholding Pattern

As of Jun 2026
Promoters 69.87%
DIIs 15.94%
Public 6.97%
FIIs 4.18%
Others 3.03%
Total 99.99%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
69.48%
69.48%
69.48%
69.48%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.67%
69.67%
69.74%
69.74%
69.74%
69.87%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
4.52%
4.46%
4.32%
3.94%
4.17%
3.94%
3.96%
4.05%
4.24%
4.25%
4.18%
DIIs
10.92%
11.17%
11.36%
11.56%
11.69%
12.06%
12.43%
12.76%
13.31%
13.40%
13.93%
14.50%
15.38%
15.47%
16.05%
16.06%
16.43%
16.46%
16.30%
16.17%
16.18%
15.94%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
10.99%
10.78%
11.43%
9.57%
9.22%
8.91%
9.12%
9.21%
9.08%
8.98%
8.24%
8.00%
7.41%
7.48%
7.36%
7.26%
7.07%
7.01%
6.93%
6.87%
6.86%
6.97%
Others
8.61%
8.57%
7.73%
9.39%
9.47%
9.41%
8.84%
8.42%
8.00%
8.01%
8.22%
3.37%
3.14%
3.13%
3.04%
2.90%
2.88%
2.89%
2.99%
2.98%
2.96%
3.03%
No. of Shareholders
0
0
99,809
1,01,686
1,23,059
1,10,038
1,06,437
1,01,457
1,03,811
97,607
89,552
85,212
76,567
74,829
91,429
93,944
91,336
89,013
89,969
87,000
86,432
86,796

Documents

Frequently Asked Questions about Alembic Pharmaceuticals Ltd

What does Alembic Pharmaceuticals Ltd do?
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.
Where is Alembic Pharmaceuticals Ltd (APLLTD) listed?
Alembic Pharmaceuticals Ltd is listed on the Indian stock exchanges. It is listed on NSE: APLLTD and BSE: 533573. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Alembic Pharmaceuticals Ltd belong to?
Alembic Pharmaceuticals Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd has a market capitalisation of approximately ₹16380.59 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Alembic Pharmaceuticals Ltd?
The Price-to-Earnings (PE) ratio of Alembic Pharmaceuticals Ltd is 23.39. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Alembic Pharmaceuticals Ltd?
Over the past 52 weeks, Alembic Pharmaceuticals Ltd has traded between a low of ₹635.8 and a high of ₹1,002. This range helps investors understand the stock's price volatility and recent trading levels.
Does Alembic Pharmaceuticals Ltd pay dividends?
Yes, Alembic Pharmaceuticals Ltd has a dividend yield of 1.46%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd has a Return on Equity (ROE) of 11.83%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Alembic Pharmaceuticals Ltd on Tapetide?
On Tapetide, you can view Alembic Pharmaceuticals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.

Website alembic-india.com
CEO Mr. Chirayu Ramanbhai Amin
Employees 16,571
Listed 2011-09-20
Face Value ₹ 2
Issued Size 19,65,63,124

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List